X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Kidney Cancer UK Gains Breakthrough NICE Clinical Funding

Content Team by Content Team
21st November 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Through its approach to NHS England, the non-profit organisation Kidney Cancer UK was able to gain funding for the National Institute for Health and Care Excellence (NICE) to create the first-ever clinical guidelines for the disease.

The organisation conducted an extensive study over a six-year period, closely collaborating with professionals in all facets of kidney cancer treatment through its Kidney Cancer UK Accord group. Using information from NHS Digital, the group—which consists of top kidney cancer physicians, oncologists, clinical nurse specialists, patients, and caregivers—commissioned a two-year service quality assessment of more than 18,000 kidney cancer patients. It is thought to be the biggest audit of kidney cancer ever done.

The findings showed substantial regional variance and reaffirmed the importance of early diagnosis and prompt initiation of treatment for kidney cancer.

According to the most recent results of Kidney Cancer UK’s patient survey, 30% of patients wait more than three months between receiving a diagnosis and starting treatment. The commission’s recommendations are intended to benefit this subset of patients.

In a statement to the Kidney Cancer UK Accord Group, Dr. Kate Fife, consultant clinical oncologist at Cambridge University Hospital, said an audit had shown that, among those whose tumour phase was known, over 21% were identified when tumours were usually not curable, and only 25% of these patients did survive for two years. 87% of patients were still living at two years if kidney cancer was discovered in its early stages, when it may still be treated. This emphasises how crucial early diagnosis is.

The analysis discovered significant differences in surgical and pharmaceutical therapy amongst the 21 cancer alliances, and much more so within various hospital trusts, according to Professor Grant Stewart, Professor of Surgical Oncology at the University of Cambridge. Similarly, between 40% and 70% of patients with metastatic kidney cancer got anti-cancer medications. Once implemented, these long-delayed NICE guidelines will have a positive effect on patients’ experiences throughout their journey and will eliminate these contradictions.

Geraldine Fox, a kidney cancer patient and participant in the Kidney Cancer UK Accord group, observed that Kidney cancer has long been a neglected cancer. All ten of the malignancies that are most common in the UK have guidelines that are periodically reviewed, with the exception of kidney cancer, which has received zero attention.

Previous Post

WHO Emergency May Compel Big Pharma To Declare State Deals

Next Post

Nasal Vaccination Improves COVID-19 Protection In Australia

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Nasal Vaccination Improves COVID-19 Protection In Australia

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In